Table 1.
Demographics, clinical characteristics, and serum sample availability for 14 Zika and 60 dengue cases confirmed by RT-PCR
| Characteristics | Zika cases (N = 14) | Dengue cases (N = 60) |
|---|---|---|
| Number (%) or median (interquartile range) | ||
| Demographic | ||
| Male | 6 (42.9) | 31 (51.7) |
| Age | 22.5 (15–41) | 18 (10–34) |
| Clinical Manifestations | ||
| Headache | 13 (92.9) | 58 (96.7) |
| Myalgia | 12 (85.7) | 46 (76.7) |
| Retro-orbital pain | 10 (71.4) | 34 (56.7) |
| Arthralgia | 8 (57.1) | 28 (46.7) |
| Vomit | 2 (14.3) | 12 (20.0) |
| Rash | 10 (71.4) | 6 (10.0) |
| Pruritus | 10 (71.4) | NA |
| Prior dengue infectiona | ||
| No | 1 (8.3) | 13 (21.7) |
| Yes | 11 (91.7) | 47 (78.3) |
| Blood sample collected | ||
| Acute-phase sample | 14 (100) | 60 (100) |
| Time between symptoms onset and sample collection | 2.5 (2–4) | 2 (1–3) |
| Convalescent-phase sample | 8 (57.1) | 60 (100) |
| Time between symptoms onset and sample collection | 27 (18.5–43.5) | 27 (19.5–57.5) |
| Sera tested by ZIKV ELISAb | ||
| ZIKV IgM-ELISA in acute-phase sera | 14 (100) | 58 (96.7) |
| ZIKV IgM-ELISA in convalescent-phase sera | 8 (57.1) | 59 (98.3) |
| ZIKV IgG-ELISA in acute-phase sera | 13 (92.9) | NT |
| ZIKV IgG-ELISA in convalescent-phase sera | 8 (57.1) | 60 (100) |
NT = Not tested
aPrior dengue infection was determined by a positive result in the DENV IgG-ELISA performed in the acute-phase serum sample
bSome patients did not have their acute- or convalescent serum sample tested for ZIKV because of insufficient volume of sera